全文获取类型
收费全文 | 1409024篇 |
免费 | 101425篇 |
国内免费 | 3092篇 |
专业分类
耳鼻咽喉 | 20893篇 |
儿科学 | 42366篇 |
妇产科学 | 40545篇 |
基础医学 | 197480篇 |
口腔科学 | 42213篇 |
临床医学 | 119943篇 |
内科学 | 275616篇 |
皮肤病学 | 32196篇 |
神经病学 | 114104篇 |
特种医学 | 57128篇 |
外国民族医学 | 437篇 |
外科学 | 220427篇 |
综合类 | 31594篇 |
现状与发展 | 6篇 |
一般理论 | 539篇 |
预防医学 | 96638篇 |
眼科学 | 33060篇 |
药学 | 105149篇 |
2篇 | |
中国医学 | 3108篇 |
肿瘤学 | 80097篇 |
出版年
2018年 | 14076篇 |
2016年 | 12737篇 |
2015年 | 13959篇 |
2014年 | 19337篇 |
2013年 | 29121篇 |
2012年 | 38537篇 |
2011年 | 40715篇 |
2010年 | 23903篇 |
2009年 | 22644篇 |
2008年 | 38604篇 |
2007年 | 41957篇 |
2006年 | 42108篇 |
2005年 | 40587篇 |
2004年 | 39417篇 |
2003年 | 38280篇 |
2002年 | 37503篇 |
2001年 | 65398篇 |
2000年 | 67380篇 |
1999年 | 56405篇 |
1998年 | 14500篇 |
1997年 | 13158篇 |
1996年 | 12512篇 |
1995年 | 12529篇 |
1994年 | 11752篇 |
1992年 | 43171篇 |
1991年 | 41674篇 |
1990年 | 40898篇 |
1989年 | 39897篇 |
1988年 | 37261篇 |
1987年 | 36712篇 |
1986年 | 35206篇 |
1985年 | 33477篇 |
1984年 | 25164篇 |
1983年 | 21310篇 |
1982年 | 12894篇 |
1981年 | 11781篇 |
1979年 | 24168篇 |
1978年 | 17265篇 |
1977年 | 14996篇 |
1976年 | 13566篇 |
1975年 | 15418篇 |
1974年 | 18242篇 |
1973年 | 17752篇 |
1972年 | 16947篇 |
1971年 | 15841篇 |
1970年 | 15014篇 |
1969年 | 14457篇 |
1968年 | 13569篇 |
1967年 | 12101篇 |
1966年 | 11358篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
1.
Härter Martin Koch-Gromus Uwe 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(3):267-269
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - 相似文献
2.
Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways 下载免费PDF全文
Ahmed A Abd-Rabou Hanaa H Ahmed Safaa H MohamedSoheir E KotobMohamed S Kishta 《Asian Pacific journal of cancer prevention》2022,23(12):4261-4273
Objective: Hepatocellular carcinoma (HCC) microenvironment has been recognized as a key contributor for cancer progression, metastasis, and drug resistance. The crosstalk between tumor cells, the vascular endothelial growth factor (VEGF), and the chemokine (C-C motif) ligand 2 (CCL2) signaling networks mediates immunoinhibitory impact and facilitates tumor angiogenesis. The current investigation aimed at exploring the potent anti-cancer activity of the newly designed nano-based anti-cancer therapy comprising anti-VEGF drug, avastin (AV), and CCR2 antagonist (CR) to counteract HCC and tracking its mode of action in vivo. Methods: The prepared AV, CR, and AVCR nanoprototypes were characterized by nanoscale characterization techniques in our previous work. Here, they are applied for unearthing their anti-cancer properties / mechanisms in hepatic cancer-induced rats via analyzing protein levels and genetic expression of the elements incorporated in the angiogenesis, apoptosis, and metastasis signalling pathways. Results: The present results revealed a significant down-regulation in the angiogenesis, survival and metastasis indices along with up-regulation in the pro-apoptotic mediators upon treatment of hepatic cancer-bearing rats with the novel synthesized nanomaterials when compared with the untreated counterparts. We showed across HCC model that anti-VEGF in combination with CCR2 antagonism therapy leads to sensitization and enhanced tumor response over anti-VEGF or CCR2 antagonism monotherapy, particularly in its nanoscale formulation. Conclusion: The present approach provides new mechanistic insights into the powerful anti-hepatic cancer advantage of the novel nanoprototypes which is correlated with modulating critical signal transduction pathways implicated in tumor microenviroment such as angiogenesis, apoptosis and metastasis. This research work presents a substantial foundation for future studies focused on prohibiting cancer progression and recovery by targeting tumor microenviroment. 相似文献
3.
4.
5.
Siegler Benedikt Hermann Oehler Beatrice Kranke Peter Weigand Markus Alexander 《Der Anaesthesist》2022,71(8):646-660
Die Anaesthesiologie - Der Postpunktionskopfschmerz („postdural puncture headache“, PDPH) zählt zu den wesentlichen Komplikationen der peripartalen neuroaxialen Analgesie. Als... 相似文献
6.
Matthias Knefel PhD Elisabeth L. Zeilinger PhD Simone Lubowitzki PhD Katharina Krammer MSc Matthias Unseld MD Rupert Bartsch MD Thorsten Fuereder MD Ulrich Jäger MD Barbara Kiesewetter MD Maria Krauth MD Markus Raderer MD Philipp B. Staber MD Peter Valent MD Alexander Gaiger MD 《Cancer》2023,129(21):3466-3475
Background
Survival in cancer patients is associated with a multitude of biological, social, and psychological factors. Although it is well established that all these factors add to overall mortality, it is not well understood how the predictive power of these parameters changes in a comprehensive model and over time.Methods
Patients who attended the authors’ outpatient clinic were invited to participate. The authors followed 5180 mixed cancer patients (51.1% female; mean age, 59.1 years [SD = 13.8]) for up to 16 years and analyzed biological (age, sex, cancer site, anemia), psychological (anxiety, depression), and social variables (marital status, education, employment status) potentially predicting overall survival in a Cox proportional hazards model.Results
The median survival time for the entire sample was 4.3 years (95% confidence interval, 4.0–4.7). The overall survival probabilities for 1 and 10 years were 76.8% and 38.0%, respectively. Following an empirical approach, the authors split the time interval into five periods: acute, subacute, short-term, medium-term, and long-term. A complex pattern of variables predicted overall survival differently in the five periods. Biological parameters were important throughout most of the time, social parameters were either time-independent predictors or tended to be more important in the longer term. Of the psychological parameters, only depression was a significant predictor and lost its predictive power in the long-term.Conclusions
The findings of this study allow the development of comprehensive patient-specific models of risk and resilience factors addressing biopsychosocial needs of cancer patients, paving the way for a personalized treatment plan that goes beyond biomedical cancer care. 相似文献7.
8.
9.
Cynthia S. E. Hendrikse MD Phyllis van der Ploeg MD PhD Nienke M. A. van de Kruis MD Jody H. C. Wilting MD Floor Oosterkamp BSc Pauline M. M. Theelen MSc Christianne A. R. Lok MD PhD Joanne A. de Hullu MD PhD Huberdina P. M. Smedts MD PhD M. Caroline Vos MD PhD Brenda M. Pijlman MD Loes F. S. Kooreman MD Johan Bulten MD PhD Marjolein H. F. M. Lentjes-Beer MD PhD Steven L. Bosch MD PhD Anja van de Stolpe MD PhD Sandrina Lambrechts MD PhD Ruud L. M. Bekkers MD PhD Jurgen M. J. Piek MD PhD 《Cancer》2023,129(9):1361-1371
Background
Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.Results
Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS. 相似文献10.